60 health systems sign Epic’s letter against interoperability rule

An HHS rule that would enable patients to have free access to their medical records through third-party digital apps is facing a tough battle. One of the biggest EMR vendor companies, Epic Systems, is leading the opposition to the rule, after its CEO Judy Faulkner penned a letter to HHS Secretary Alex Azar arguing against it.

About 60 other health systems have signed onto Faulkner’s letter, CNBC reported, including Atrius Health, University Health System and more.

While Epic says it is supportive of the concept of the interoperability rule, which is expected to impact 125 million patients overall, it cited concerns about health system burdens and potential dangers to patient privacy and information for its opposition.

The interoperability rule is a key part of CMS Administrator Seema Verma’s plan to increase transparency for patients and lower costs. With more ability to view and access their healthcare data, patients will be able to make better choices and ultimately help bring down healthcare costs, according to CMS.

Epic’s critiques of the rule offer some changes, including a longer timeline to prepare and implement the application programming interfaces (APIs) and more clarity around family members, CNBC noted. Congress has also requested more information from HHS about security concerns under the rule.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.